TP53 and acute myeloid leukemia: created a novel model of therapy-related AML using a Trp53-targeting shRNA to knock down expression of p53 in bone marrow cells harvested from transgenic mice harboring heterozygous loss of Erg1 and Apc, two genes located on the long arm of chromosome 5, and thus lost in AML with 5q deletion (161).